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ts@umcgAbstract Objective: To determine the prevalence, localisation and type of occult (non)inva-
sive cancer in risk-reducing salpingo-oophorectomy (RRSO) specimens in BRCA-mutation
carriers and high-risk women from BRCA-negative families.
Methods: A consecutive series of RRSO specimens of asymptomatic, screen-negative high-risk
women were prospectively collected in our tertiary multidisciplinary cancer clinic from Janu-
ary 2000 until March 2012. All high-risk women in this study underwent genetic testing on
BRCA-mutations. The surgico-pathological protocol comprised complete resection of ovaries
and fallopian tubes, transverse sectioning at 2–3 mm (sectioning and extensively examining the
ﬁmbrial end [SEE-FIM] protocol from 2006) and double independent pathology review of
morphologically deviant sections.
Results: Three hundred and sixty RRSOs were performed in 188 BRCA1-carriers, 115
BRCA2-carriers and 57 BRCA-negative women at a median age of 44.0 years. Four occult
invasive cancers were detected in BRCA-carriers (1.3%, 95%-conﬁdence interval (CI) 0.03–
2.61), all in BRCA1-carriers >40 years of age. All cancers, of which two tubal and two ovarian
cancers, were FIGO-stage I/II. Three non-invasive serous intraepithelial carcinomas (STICs)
were detected in BRCA-carriers (1.0%, 95%-CI 0.00–2.10). In BRCA-negative women onelsevier Ltd. All rights reserved.
21
ision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Groningen,
anzeplein 1, P.O. Box 30.0001, 9700 RB Groningen, The Netherlands. Tel.: +31 50 361 3008; fax: +31 50
.nl (M.J.E. Mourits).
W. Reitsma et al. / European Journal of Cancer 49 (2013) 132–141 133STIC was found (1.8%, 95%-CI 0.00–5.16), however she carried an unclassiﬁed variant in
BRCA2. Total follow-up after RRSO was 1691 woman-years, in which one BRCA1-carrier
developed peritoneal cancer (0.3%, 95%-CI 0.00–0.82).
Conclusions: A low prevalence of occult invasive cancer (1.1%) was found in young asymp-
tomatic, screen-negative women at increased ovarian cancer risk undergoing RRSO. This
study adds to the advice to perform RRSO in BRCA1-carriers before the age of 40. Our ﬁnd-
ings support the hypothesis of the fallopian tube as the primary site of origin of pelvic high-
grade serous cancer.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Epithelial ovarian cancer aggregates in families. A
family history of ovarian cancer confers an increased
risk of this disease: the lifetime risk for women with
one ﬁrst-degree relative aﬀected by ovarian cancer is
3.5–7% and increases to 15% when two ﬁrst-degree rela-
tives are aﬀected.1 In approximately 10% of all ovarian
cancer cases, a deleterious BRCA1/2 germline mutation
can be detected.2,3 The lifetime risk of developing ovar-
ian cancer in women with a proven BRCA1-mutation
ranges from 18% to 54% and is 2.4–23% in BRCA2-
mutation carriers by the age of 70 years.4,5
Since the proven ineﬀectiveness of gynaecologic
screening in detecting early-stage ovarian/tubal cancer,6,7
BRCA-carriers are recommended to undergo risk-reduc-
ing salpingo-oophorectomy (RRSO). If performed at a
young age, RRSO is associated with a statistically signif-
icant reduction of the risk of BRCA-associated ovarian/
tubal cancer (hazard ratio (HR) 0.21; 95%-conﬁdence
interval (CI) 0.12–0.39).8 After RRSO, a residual risk
may exist for ‘primary’ peritoneal cancer; although
according to new insights peritoneal cancer is possibly
metastatic from tubal intraepithelial carcinoma.9,10
Occult cancers have been reported in prophylactically
removed ovaries and fallopian tubes in BRCA-carriers.
Reported rates vary considerably from 2% to 12%11,12
and seem to be inﬂuenced by patients’ age at RRSO,
symptoms, gynaecologic screening prior to RRSO, the
completeness of prophylactic surgery and the extent of
histopathological examination. Non-invasive serous
tubal intraepithelial carcinomas (STICs) have been iden-
tiﬁed in 3–12% of the prophylactically removed tubes of
BRCA-carriers, especially in the ﬁmbrial part.11,13 No
intraepithelial carcinomas have ever been found in ova-
ries so far, suggesting that ovarian cancer does not have
its origin in the ovary itself.14 The fallopian tube is cur-
rently being suggested as the primary site of origin of
pelvic high-grade serous cancer15, which has recently
been established in a mouse model.16
Aim of this study was to obtain an unbiased estimate
of the prevalence, localisation and type of occult
(non)invasive cancer in prophylactically removed ova-
ries and tubes in a consecutive series of BRCA-carriers
and high-risk women from BRCA-negative families
attending a tertiary multidisciplinary cancer clinic.2. Patients and methods
The Family Cancer Clinic (FCC) at the University
Medical Center Groningen (UMCG) is a tertiary level
clinic for managing women at hereditary or familial
high-risk for ovarian (and breast) cancer (H(B)OC).
From 1996, clinical and genetic data of all high-risk
families have been prospectively registered at the FCC
in a combined setting by a clinical geneticist, a gynaeco-
logic oncologist and a surgical oncologist.17 Genetic
testing for BRCA-mutations is available to women from
H(B)OC families (see criteria in Fig. 1).18 Women with a
conﬁrmed BRCA-mutation are being counselled to con-
sider RRSO from the age of 35 (BRCA1) or 40
(BRCA2), or as soon as childbearing after this age is
completed.18 Women from a H(B)OC family who tested
negative for BRCA-mutations (further denoted ‘BRCA-
negative high-risk women’) are also oﬀered RRSO if the
estimated lifetime risk of developing ovarian cancer is
>10%. After RRSO, women still visit the FCC for breast
cancer screening by a surgical oncologist.19
A consecutive series of RRSO specimens of BRCA1-
carriers, BRCA2-carriers and BRCA-negative high-risk
women were prospectively collected in the UMCG
between 1st January 2000 and 1st March 2012. Included
were asymptomatic women who had a negative gynae-
cologic screening (pelvic examination, transvaginal
ultrasound and serum CA125 measurement) within
1 year prior to RRSO.7 Excluded were women with
ovarian/tubal cancer prior to RRSO and women who
underwent salpingo-oophorectomy as part of breast
cancer therapy. Main outcome measures were the
prevalence and localisation of occult cancer and STIC
(primary outcomes), and of atypical hyperplasia (sec-
ondary outcome).20 An anonymous, password-pro-
tected database was used to enter the data. Protection
of the patients’ identity was guaranteed by assigning
study-speciﬁc, unique patient numbers and codes were
only known to two dedicated data managers. According
to Dutch law, no further Institutional Review Board
approval was needed for this study.
A strict surgico-pathological protocol was applied
consisting of complete resection of both tubes and ova-
ries that were transversely sectioned at 2–3 mm intervals
and processed in their entirety.21 Since Madeiros et al. in
2006 published a protocol for sectioning and extensively
Breast cancer Ovarian cancer 
One breast cancer case <35 years of age Epithelial ovarian-/tubal cancer <50 years of age 
Contralateral breast cancer with the first tumor 
<50 years of age 
Ovarian-/tubal cancer and breast cancer in the 
same family of in one patient, with at least one 
tumor <50 years of age 
One case of triple negative breast cancer <40 
years of age 
Two first-degree or one first- and one second-
degree relative with ovarian-/tubal cancer 
The occurrence of breast cancer <50 years of 
age and ovarian cancer in a first-degree relative 
The occurrence of a male breast cancer 
Two breast cancer cases in first-degree relatives 
with at least one case <50 years of age 
Three or more first-degree relatives with breast 
cancer in two successive generations with at least 
one case <50 years of age 
Breast or ovarian cancer <50 years of age and 
prostate cancer <60 years in the same family 
Fig. 1. Deﬁnition of women at high-risk of breast and/or ovarian cancer: criteria for BRCA mutation testing established by the Netherlands
Foundation for the Detection of Hereditary Tumours (STOET).18
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was implemented in our study.22 From the ovaries and
fallopian tubes a small part was snap frozen for the tis-
sue bank, as according to the protocol, a haematoxylin
and eosin (H&E) section was made to check for histo-
logical abnormalities and additional immunohistochem-
ical staining of p53 and MIB-1 (Ki67) was performed.
Histopathological examination was conducted by two
expert gynaecologic pathologists (H.H. and J.B.) who
were aware of the woman’s mutation status. The H&E
sections showing morphologically atypical epithelium,
STIC or occult cancer and a sample of normal sections,
were independently revised by the other expert gynaeco-
logic pathologist without knowledge of the previous
pathologic report.
Occult cancer was deﬁned as a clinically unapparent
invasive malignancy of the epithelium of the ovary or
fallopian tube diagnosed at histopathological examina-
tion, according to the guidelines of the International
Federation of Gynecology and Obstetrics (FIGO). In
this paper, occult cancer refers to an invasive malig-
nancy and not to an in situ component. STIC was
deﬁned as an intraepithelial carcinoma that was in con-
tinuity with normal mucosal epithelium, with epithelial
stratiﬁcation, nuclear enlargement, prominent nucleoli,
variable loss of epithelial polarity and mitotic activity
(Fig. 2D–F).23 Cases with histological abnormalities
not amounting to STIC, but showing some cellular
crowding, stratiﬁcation, loss of nuclear polarity and
moderate to severe nuclear atypia, were deﬁned as atyp-
ical hyperplasia (Fig. 2A–C).20 Positive staining for p53
was not required for diagnosing atypical hyperplasia.
All BRCA1-mutation carriers presented in this paper
had a proven pathogenic mutation (splice site
mutations, nonsense mutations, frameshifts or exondeletions). Patients carrying an unclassiﬁed variant
(UV) were incorporated in the group ‘negative tested
women’. The start of follow-up after RRSO was deﬁned
as the date of RRSO and the end of follow-up as the
date of the last outpatient visit.
Statistical analysis was performed using SPSS 18.0
for Windows (SPSS, Chicago, IL). Descriptive values
of variables were expressed as frequencies and percent-
ages for discrete data and as median and range for con-
tinuous data. Diﬀerences between the groups were
investigated with the v2 test or Fisher’s exact test for dis-
crete variables and with the Mann Whitney U test or
Kruskall–Wallis test for continuous data. For each
woman, duration of follow-up was calculated. Conﬁ-
dence intervals for a single proportion were calculated
and P-values <0.05 were considered to be statistically
signiﬁcant.
3. Results
From January 2000 until March 2012, 641 women
from high-risk families visited our FCC after referral
by the clinical genetics department. In total, 360 women
underwent RRSO, among whom were 188 BRCA1-
carriers (52.2%) from 221 BRCA1-families, 115
BRCA2-carriers (31.9%) from 146 BRCA2-families and
57 BRCA-negative high-risk women (15.8%) from 45
BRCA-negative high-risk families (reference date: 1st
March 2012) (Table 1). Of the BRCA-negative women,
ﬁve had a UV in one of the BRCA-genes. Median age
at RRSO was 44.0 (range 30–72); BRCA1-carriers were
signiﬁcantly younger (42.0) than BRCA2-carriers (45.0)
and BRCA-negative women (47.0; p < 0.001). Thirty-
eight percent of the women had previously been diag-
nosed with breast cancer.
Fig. 2. Distal fallopian tube showing atypical hyperplasia (A–C) and STIC (D–F). (A) Atypical hyperplasia in a BRCA1 mutation carrier showing
cellular crowding, stratiﬁcation, loss of nuclear polarity and moderate nuclear atypia (H&E stain). P53 staining is not markedly increased (B) and
proliferation (MIB-1) is not signiﬁcantly elevated (C). (D) Distinction between serous tubal intraepithelial carcinoma (STIC; arrow) and adjacent
normal ﬁmbrial mucosal epithelium (arrowhead) in a BRCA1 carrier (H&E stain). STIC is associated with diﬀuse immunopositivity for p53 (E),
with abrupt negativity of adjacent normal epithelium (arrowhead), and markedly elevated MIB-1 (Ki67) proliferation index (F) (magniﬁcation in
all ﬁgures, 100).
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presented in Table 2. Occult cancer was detected in four
women: two fallopian tube and two ovarian cancers. All
were BRCA1-carriers and above the age of 40 (median
age 55.0) (Table 3). The overall occult cancer rate was
1.1% (95%-CI 0.03–2.19), the rate in BRCA-carriers
was 1.3% (95%-CI 0.03–2.61) and in BRCA1-carriers
2.2% (95%-CI 0.11–4.32). All four patients underwent
a surgical staging procedure and all cancers appeared
to be early stage (FIGO I/II). Patients were treated with
adjuvant chemotherapy (six courses of paclitaxel and
carboplatin). No slides or tissue blocks of distal tubes
were available from both occult ovarian cancers, most
probably because the tissue was used for other research
properties; therefore a tubal origin could not be
excluded nor proven with certainty.
Four cases of STIC (as shown in Fig. 2D–F) were
detected, all located in the fallopian tube (1.1%, 95%-
CI 0.03–2.19): one in a BRCA1-carrier (aged 60 years),
two in BRCA2-carriers (aged 50 and 57 years) and one
in a BRCA-negative woman (aged 56 years; median
age 56.5) (Table 3). The STIC rate in BRCA-carriers
was 1.0% (95%-CI 0.00–2.10) and was 1.8% (95%-CI
0.00–5.16) in BRCA-negative women.
Atypical hyperplasia (as shown in Fig. 2A–C) was
present in 23 women (6.4%, 95%-CI 3.86–8.96): 13
BRCA1, nine BRCA2 and one BRCA-negative woman(median age 41.0) (Table 4). Rates were 7.2% (95%-CI
4.34–10.18) for BRCA-carriers and 1.8% (95%-CI
0.00–5.16) for BRCA-negative women. Seventeen out
of 23 lesions were localised in the ﬁmbrial end of the
tube (73.9%). The other six atypical lesions also con-
cerned tubal epithelium either located at the ovarian sur-
face or lining epithelial ovarian inclusion cysts. The case
of STIC and the case of atypia were found in two
BRCA-negative high-risk women who however carried
a suspected pathogenic (category III) and a possibly
pathogenetic (category II) UV in BRCA, respectively.
The case of STIC concerned a 56-year-old woman with
a maternal breast/ovarian cancer family, however with a
(probably) paternal UV in BRCA2 (ALA2306Pro) who
was diagnosed with breast cancer at the age of 28. The
case of atypical hyperplasia concerned a 37-year-old
woman with a UV in BRCA1 (332-15A>G), from a
maternal breast/ovarian cancer family. Incidental
benign alterations were seen in approximately 40% of
the women, without signiﬁcant diﬀerences between
BRCA-carriers and negative tested women.
The total follow-up after RRSO concerned 1691
woman years, with a median follow-up of 5.0 years
(range 0–12) per woman. Speciﬁcally, the four patients
with occult carcinoma had a median follow-up of
7.5 years (range 6–10), the four patients with STIC
had a median follow-up of 1.0 years (range 0–6) and
Table 1
Characteristics of the study population.
BRCA1 (N = 188) BRCA2 (N = 115) BRCA-negative*
(N = 57)






No. (% or range) No. (% or
range)
At RRSO
Age at RRSO, median 42.0 (30–72) 45.0 (33–66) 47.0 (36–66) 44.0 (30–72) <0.001
Breast cancer prior to RRSO 73 (38.8) 33 (28.7) 31 (54.4) 137 (38.1) 0.005
Age at ﬁrst breast cancer (N = 139),
median
39.0 (23–63) 45.0 (30–64) 41.0 (28–53) 41.0 (23–64) 0.08
Menopausal status
Premenopausal 138 (73.4) 74 (64.3) 34 (59.6) 246 (68.3) 0.08
Postmenopausal 50 (26.6) 41 (35.7) 23 (40.4) 114 (31.7)
Time from last screening to RRSO in
months, median
3.0 (0–21) 2.0 (0–18) 2.0 (0–20) 2.0 (0–21) 0.55
Type of primary surgery
Laparoscopy 185 (98.4) 115 (100.0) 57 (100.0) 357 (99.2) 0.25
Laparotomy 3 (1.6) – – – – 3 (0.8)
Peritoneal lavage performed 141 (75.0) 95 (82.6) 51 (89.5) 287 (79.7) 0.04
Normal cells 141 (100.0) 94 (98.9) 51 (100.0) 286 99.7
Atypical cells – – 1 1.1 – – – 0.3
Malignant cells – – – – – – – –
Following RRSO
Current age, median 48.0 (31–77) 50.0 (38–75) 53.0 (36–72) 49.0 (31–77) 0.02
Median follow–up, years 5.0 (0–12) 4.0 (0–9) 4.0 (0–9) 5.0 (0–12) 0.001
Total 1003 482 206 1691
Deceased at the end of the study# 5 (2.7) 3 (2.6) 1 (1.8) 9 (2.5) 0.66
In 1 BRCA1 and 3 BRCA2 mutation carriers RRSO was performed before mutation status was known.
* Including ﬁve women with UV mutation in one of the BRCA genes: two unlikely pathogenic (category 2 UV) and three possibly pathogenic
(category 3 UV) (Bell’s classiﬁcation).
 Atypical cells: this patient was diagnosed with endometrioid type endometrial cancer 7 months after RRSO (n = 1).
# BRCA1 due to ovarian (n = 1) and breast cancer (n = 4); BRCA2 due to breast cancer (n = 1), pancreas cancer (n = 1) and a non-malignant
cause (n = 1); negative tested due to breast cancer (n = 1).
136 W. Reitsma et al. / European Journal of Cancer 49 (2013) 132–141the 23 women with atypical hyperplasia had a median
follow-up of 5.0 years (range 0–11). None of the women
with STIC or atypical hyperplasia developed peritoneal
cancer. One patient, carrying a BRCA1-mutation, devel-
oped peritoneal cancer 4.2 years after a RRSO (0.3%,
95%-CI 0.00–0.82). Careful histological re-examination
of the ovaries and tubes (including immunohistochemi-
cal staining of p53 and MIB-1) was performed, which
assured the complete removal of both ovaries and tubes,
and revealed atypical hyperplasia in the left distal fallo-
pian tube.
4. Discussion
To date, this is the largest consecutive series of pro-
spectively collected RRSO specimens in BRCA-carriers
and BRCA-negative high-risk women attending a ter-
tiary multidisciplinary cancer clinic. Our study showed
a low prevalence of occult cancer (1.1%) and STIC
(1.1%), exclusively in BRCA-carriers or women with a
UV. Two of the four cancers could be proven to origi-
nate from the fallopian tube, and all STICs and atypical
hyperplastic lesions were derived from tubal epithelium.
Strengths of this study are the consecutive and uniformseries of asymptomatic, screen-negative high-risk
women, the independent histopathological revision of
the morphologically deviant sections by another expert
gynaecologic pathologist, the clear distinction between
BRCA-positive and BRCA-negative cases, the large
sample-size, the prospective nature of the study and
the long duration of follow-up. A limitation was the
unavailability of two specimens for histopathological
revision.
We found a low prevalence of occult cancer at RRSO
of 1.3% in BRCA-carriers. Reported prevalence of
occult cancer in BRCA-carriers varies considerably,
from 2% to 3% in large, mainly multicentre ser-
ies,9,12,13,24,25 to 7% to 12% in smaller, particularly sin-
gle-centre series.11,26,27 The lower cancer prevalence in
our series might be explained by age at RRSO, which
was 43 years in our series compared to approximately
48 years in the latter.11,26–28 Furthermore, the majority
of these studies did not select women on absence of
symptoms for the presence of ovarian cancer, nor per-
formed gynaecological screening prior to RRSO rou-
tinely and advanced stage cancers were not
uncommon.11,26,27 We believe that the selection of
young, asymptomatic, screen-negative women for
Table 2
Histomorphological ﬁndings at RRSO.
Histomorphology
epithelium
BRCA1 (N = 188) BRCA2 (N = 115) BRCA-negative* (N = 57) Total (N = 360) P value
Tubes Ovaries Tubes Ovaries Tubes Ovaries Tubes Ovaries
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Occult carcinoma 2 (1.1) 2 (1.1) – – – – – – – 2 (0.6) 2 (0.6) 0.16
STIC 1 (0.5) – – 2 (1.7) – – 1 (1.8) – – 4 (1.1) – – 0.55
Atypical hyperplasia 11 (5.9) 2 (1.1) 6 (5.2) 3 (2.6) – 1 (1.8) 17 (4.7) 6 (1.7) 0.28
Reactive changes 2 (1.1) 9 (4.8) 2 (1.7) 8 (7.0) – – 2 (3.5) 4 (1.1) 19 (5.3) 0.53
Metaplasia – – 1 1 – – 1 1
Hyperplasia 1 7 – 7 – 2 1 16
Proliferation 1 2 1 – – – 2 2
Benign alterations 68 (36.2) 82 (43.6) 36 (31.3) 56 (48.7) 23 (40.4) 39 (68.4) 127 (35.3) 177 (49.2) 0.27
Epithelial inclusion cysts – 46 – 31 – 17 – 94
Para tubal cysts 37 – 22 – 13 – 72 –
Papillomatosis – 1 – 3 – 3 – 7
Adenoﬁbroma 2 4 – 6 – 3 2 13
Serous cystadenoma – 6 – 1 – 4 – 11
Dermoid cyst – 3 – 1 – 2 – 6
Brenner tumor – 4 – 1 – 1 – 6
Haemangioma – 1 – 1 – – – 2
Endometriosis – 2 1 5 1 5 2 12
Endosalpingiosis 2 – 2 – – – 4 –
Walthard cell rest 17 1 11 1 7 2 35 4
Mesonephric rests 10 7 – 3 2 2 12 12
Ectopic adrenal tissue – 1 – 2 – – – 3
Leydig–cell hyperplasia – 3 – 1 – – – 4
Rete ovarii – 3 – – – – – 3
* Including ﬁve women with UV mutation in one of the BRCA genes: two unlikely pathogenic (category 2 UV) and three possibly pathogenic (category 3 UV) (Bell’s classiﬁcation).
 Multiple abnormalities per woman: in 33.3% (120/360) women no histomorphological abnormalities were found; 35.8% (129/360) women had one lesion (carcinoma, STIC, atypical, reactive or



























































































































































































































































































































































































































































































































































































































































































































































































138 W. Reitsma et al. / European Journal of Cancer 49 (2013) 132–141RRSO, contributes to the ﬁnding of a low occult cancer
frequency at RRSO.
Occult cancers in our series were exclusively found in
BRCA1-carriers above age 40 (2.2%). This is consistent
with literature and can be explained by the higher pene-
trance of ovarian cancer in BRCA1- as compared to
BRCA2-carriers.9,13,25,29
Three STICs were detected in BRCA-carriers (1.0%):
one in a BRCA1-carrier and two in BRCA2-carriers.
STIC has been reported in 3–12% of the prophylacti-
cally removed ovaries and fallopian tubes in BRCA-car-
riers, mostly in the ﬁmbrial end of the tube.11,13,28,30–32
Our ﬁnding of 1.0% STICs in BRCA-carriers is at the
lower end of the reported range, which could be
explained by the consecutive series of asymptomatic car-
riers (no case-ﬁnding), the relatively young age at RRSO
and the strict deﬁnitions used. Twenty-three atypical
hyperplastic lesions (7.2%) were detected in BRCA-car-
riers. In a recent clinicopathological study of 117
RRSO-specimens of BRCA-carriers, atypia was
reported in ﬁve cases.32
Limited data are available on the occult cancer rate in
prophylactically removed ovaries and fallopian tubes in
BRCA-negative high-risk women. Few clinicopatholog-
ical RRSO studies included a small number of BRCA-
negative women and none of them found occult cancer
or STIC in these women.6,11,12,28,33,34 We found one
STIC (1.8%) and one atypical hyperplastic lesion
(1.8%) in BRCA-negative women; however both women
had a UV BRCA-mutation. UV mutations in the
BRCA-genes are a frequently occurring problem in
genetic counselling of breast and/or ovarian cancer fam-
ilies. Data about the cancer history of the probands and
their families are now being used to build a model for
evaluating the clinical signiﬁcance of UV mutations in
the medical practice.35
The tubal epithelium was the primary origin of half
of the occult cancers, all cases of STIC and all atypical
hyperplastic lesions. Other studies demonstrate at least
40% of the occult cancers being located in the (distal)
fallopian tube.9,11,25,30,31,33,36 In the two ovarian cancers
in our series, of tubal origin could not be studied as no
fallopian tube slides were available or tissue blocks seen
anymore. Intraepithelial carcinoma (STIC) has only
been described in the ﬁmbrial end of the fallopian tube
and never in the ovary.14 The atypical hyperplastic
lesions were either located in the fallopian tube (17/23)
or were most likely derived from the fallopian tube (6/
23), concerning atypical tubal epithelium located at the
ovarian surface or lining epithelial inclusion cysts. These
ﬁndings might further designate the distal fallopian tube
as the primary site of high grade serous cancer.
The diagnosis of atypical hyperplasia with cytological
features that fall short of STIC remains controversial.
The clinical signiﬁcance of these lesions in the develop-
ment of ovarian cancer is unclear; however none of the
Table 4











1 2007, 41 No BRCA2 – Ovarian surface 61 NED
2 2002, 38 No BRCA1 – Fallopian tube 120 NED
3 2002, 45 Yes, bilateral, 43 BRCA1 – Ovarian inclusion cyst 113 NED
4 2002, 41 No BRCA1 – Fallopian tube 112 NED
5 2003, 39 No BRCA1 – Fallopian tube 109 NED
6 2003, 43 No BRCA1 – Fallopian tube 108 NED
7 2004, 37 No BRCA2 – Fallopian tube 90 NED
8 2005, 31 No BRCA1 – Fallopian tube 84 NED
9 2005, 42 No BRCA1 – Fallopian tube 83 NED
10 2005, 43 No BRCA1 – Fallopian tube 83 NED
11 2005, 45 No BRCA1 – Fallopian tube 82 NED
12 2006, 53 Yes, unilateral, 52 BRCA2 – Ovarian surface 64 NED
13 2008, 41 No BRCA2 – Fallopian tube 42 NED
14 2008, 50 Yes, unilateral, 49 BRCA1 – Fallopian tube 41 NED
15 2009, 41 No BRCA2 – Fallopian tube 32 NED
16 2010, 57 No BRCA2 – Ovarian inclusion cyst 26 NED
17 2010, 47 No BRCA1 – Fallopian tube 17 NED
18 2000, 48 Yes, unilateral, 44 BRCA1 – Ovarian inclusion cyst 136 NED
19 2012, 41 Yes, unilateral, 41 BRCA1 – Fallopian tube 0 NED
20 2012, 40 No BRCA2 – Fallopian tube 1 NED
21 2011, 58 No BRCA2 – Fallopian tube 9 NED
22 2006, 38 No BRCA2 – Fallopian tube 65 NED
23 2008, 37 No UV mutation
in BRCA1
– Ovarian surface 41 NED
Abbreviations: STIC, serous tubal intraepithelial carcinoma; FIGO, International Federation of Gynecology and Obstetrics; FCC, Family Cancer
Clinic; NED, no evidence of disease (=ovarian/tubal/peritoneal cancer).
W. Reitsma et al. / European Journal of Cancer 49 (2013) 132–141 139women diagnosed with atypia in our study developed
cancer. More patients with this ﬁnding need to be studied
to determine whether it has any relationship to the devel-
opment of STIC. The presence of STIC on the other
hand, has been linked as being a pre-invasive phase of
ovarian and peritoneal cancer.10,15,23,37 The likelihood
of developing peritoneal cancer after RRSO has been
estimated to be 1%.24,25,31,33,38 During a total follow-
up after RRSO of 1.691 woman years, one peritoneal
cancer has been diagnosed in a BRCA1-carrier 4.2 years
after RRSO. This low frequency of peritoneal cancer
after RRSO makes it less likely that biologically signiﬁ-
cant lesions as occult cancer and STIC have been missed.
Although the fallopian tube is suggested to be the pri-
mary origin of tumourigenesis in BRCA-carriers, the
ovary may be the preferred site for tumours to progress
beyond the microscopic stage.29 A bilateral salpingec-
tomy per se has recently been put forward as a
temporary risk-reducing surgical procedure for BRCA-
carriers, removing the tissue with the greatest malignant
potential and avoiding the oestrogen deprivation symp-
toms of the bilateral oophorectomy.39,40 However,
caution is needed with translating the tubal hypothesis
into clinical practice before it is proven. Besides, even
if the fallopian tubes are removed, dysplastic cells may
have already spread to the ovary earlier, still resulting
in a risk of ‘ovarian’ cancer.29
Our study, covering a 12-year period, shows a low
prevalence of occult cancer and STIC in young asymp-tomatic, screen-negative women at increased ovarian
cancer risk undergoing RRSO. As occult cancers were
exclusively found in BRCA1 above the age of 40, our
ﬁndings add to the advice for BRCA1-carriers to
undergo RRSO before the age of 40. In BRCA-negative
high-risk women, STIC was only found in one woman
with a BRCA UV. It is important that clinicians are
made aware of these issues, as they have implications
for counselling high-risk women. Our ﬁndings support
the hypothesis of the fallopian tube as the primary site
of origin of pelvic high-grade serous cancer. It also
underscores the importance of complete removal and a
strict histopathological sectioning protocol.Financial support
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